Moderators:
Search This Board: 
Created: 10/19/2005 06:04:42 AM - Followers: 22 - Board type: Free - Posts Today: 0
Lorus Therapeutics Implements Name Change to Aptose Biosciences
http://finance.yahoo.com/news/lorus-therapeutics-implements-name-change-110000907.html;_ylt=AwrTWf0ydBdUH3AAFBWTmYlQ

----------------------------------------------------------------------------------
 

Business Information:

Aptose Biosciences. Inc.
Ticker: APTO
PPS: 1.64    a/o     7/13/2017
Up 0.12 points or 7.89%
 
Market Value: $23,895,510 a/o July 12, 2017
Outstanding Shares: 15,721,388 a/o Dec 31, 2016
 
APTOSE Website: http://aptose.com/

Fundamental analysis:

According to Aptoses’ website, Aptose Biosciences is a biotechnical company that looks to find treatments for cancers. These cancers include acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies.
 
From their research, they have discovered that “CG026806 (CG’806) is a highly potent first-in-class pan-FLT3/BTK inhibitor.” This knowledge is aiding their fight against chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), large B cell lymphoma (DLBCL), and more. Aptose also has another program called APTO-253 which is also aiding to treat cancer.
 
Aptose Management:
William G. Rice, Ph.D.  Chief Executive Officer (CEO)
Daniel D. Von Hoff, M.D., F.A.C.P. Senior Vice President, Medical Affairs
Stephen B. Howell, M.D. Acting Chief Medical Officer
Avanish Vellanki Chief Business Officer (CBO)
Gregory Chow Chief Financial Officer (CFO)                  
 
Institutional Ownership 11.11 %
Total Institutional Shares: 2,417,492
No Insider Traders
Possible Float: ~13,303,896
Looking at Aptoses’ income statement, they have a running loss with $0 in revenue. For the first quarter of 2017, the company had a net loss of ~$4,355,000. Also, over the course of the last year, the company has had a net loss of ~$17,910,000. Unless the company can create and sell one of their cures, Aptose will continue to run at a loss. If the company was to sell one of their cures, it comes down to how effective and efficient the drug is. These medicines would help it penetrate a full cancer treatments market. There is the possibility that the drugs and treatments could sell very well, but there is serious doubt that such an event will happen.
 
Aptoses’ balance statement shows that it has ~11,958,000 in on hand cash Q1 2017. From what we were able to find, the company is gaining on-hand cash from selling company shares to investors. In total, Aptose has a total of ~$12,676,000 in assets for Q1 2017. For accounts payable, Aptose has ~$2,340,000 in current liabilities. For shareholders equity, investors of Aptose have ~$235,869,000 in shares. The accumulated deficit for investors is ~$247,877,000.
 
On 6/8/2017, the company got rated as neutral by Rodman & Renshaw. Also, analysts rated the stock as a buy with a price target of $9. In forward-looking thoughts, $9 is a very optimistic number to put on a stock that currently doesn’t have any income, and is relying solely on investors. Our forward-looking though suggests that the stock will continue its period of consolidation until either they run out of funds or release a new product. Depending on the event, the price per share will reflect the positive or negative aspects of that event.
 
On 6/6/2017, the company held an annual meeting of shareholders. During this press release, the voting results for the company’s board of directors were released. Also, the company told shareholders that they displayed CG’806 in a presentation last month in Boston. From the press release, they stated that the product/treatment was performing well during their tests.

http://www.greenpennystocks.net/2017/08/aptose-biosciences-inc-forward-looking.html" rel="nofollow">Read More Here

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#163
Well.....another M.D. with serious credentials has been hired Zeppo 09/13/2022 10:19:52 AM
#162
I haven't had enough time to research this XenaLives 09/08/2022 11:17:42 AM
#161
The company would have to receive some sort Zeppo 09/08/2022 10:31:18 AM
#160
Unfortunately not much going on here... XenaLives 09/08/2022 07:31:27 AM
#159
Seeking Alpha put out a fairly negative article Zeppo 07/25/2022 02:31:39 PM
#158
APTOSE still needs time, I believe they will Pablo Bio 06/15/2022 06:45:34 PM
#157
I see you have swung over to the Zeppo 06/15/2022 11:54:50 AM
#156
Time to go all in here! herbied47 06/14/2022 12:45:38 PM
#155
I am hopeful this will happen by end Pablo Bio 06/09/2022 09:40:38 AM
#154
The problem has been the continuous search for Zeppo 06/08/2022 12:27:13 PM
#153
New compound, new force foe a gain, hang Pablo Bio 05/12/2022 02:37:37 PM
#152
The company has a new update on its Zeppo 12/14/2021 02:04:03 PM
#151
Take out those 99 cent stop lost. willlbone 12/14/2021 10:52:14 AM
#150
WOW Aptose Biosciences (APTO) Receives a Buy from JonesTrading Source: TipRank abracky 12/08/2021 11:31:07 AM
#149
That one complete response has turned into five. Zeppo 12/07/2021 02:27:15 PM
#147 Aptose appears to be in an enviable spot. Zeppo 08/13/2021 11:36:23 AM
#146 * * $APTO Video Chart 03-24-2021 * * ClayTrader 03/24/2021 03:54:45 PM
#145 What kind of numbers do you two actually Zeppo 03/24/2021 02:16:08 PM
#144 Heavy dilution? Looks like a pump and dump PStockPickz 03/24/2021 12:48:35 PM
#143 Making nothing in margins and losing huge on make it happen 03/24/2021 08:29:28 AM
#142 $$$ 420man 03/23/2021 04:46:02 PM
#141 Well....only six people have created the twelve posts Zeppo 12/21/2020 09:38:56 AM
#140 No takers? Zeppo 12/14/2020 11:34:18 AM
#139 So......what really happened here? Zeppo 12/11/2020 02:54:01 PM
#138 * * $APTO Video Chart 12-07-2020 * * ClayTrader 12/07/2020 05:48:41 PM
#137 Link to September corporate presentation: XenaLives 09/29/2020 07:45:39 AM
#136 Public Offering of Common Shares – In July, XenaLives 09/29/2020 07:44:51 AM
#135 OVERVIEW XenaLives 09/29/2020 07:42:40 AM
#134 Short interest XenaLives 09/29/2020 07:35:04 AM
#133 APTO - 46% institutional ownership XenaLives 09/29/2020 07:24:39 AM
#132 CG 806 AACR abstract presentation 4/27, something to nferna 04/15/2020 04:28:00 PM
#131 Futures Fall Sharply STOCK MARKET TODAY Dow Jones abracky 03/15/2020 07:16:09 PM
#130 I can't believe there is no chatter on djkjpk62 03/05/2020 05:02:27 PM
#129 * * $APTO Video Chart 01-30-2020 * * ClayTrader 01/30/2020 05:35:23 PM
#128 * * $APTO Video Chart 12-20-2019 * * ClayTrader 12/20/2019 04:51:06 PM
#127 * * $APTO Video Chart 12-19-2019 * * ClayTrader 12/19/2019 04:27:32 PM
#126 * * $APTO Video Chart 12-18-2019 * * ClayTrader 12/18/2019 05:24:29 PM
#125 * * $APTO Video Chart 12-17-2019 * * ClayTrader 12/17/2019 05:49:33 PM
#124 * * $APTO Video Chart 12-11-19 * * ClayTrader 12/11/2019 05:31:56 PM
#123 * * $APTO Video Chart 12-09-2019 * * ClayTrader 12/09/2019 04:30:55 PM
#122 * * $APTO Video Chart 11-11-19 * * ClayTrader 11/11/2019 05:30:09 PM
#121 Lurking..... last 2.34 bUrRpPPP! 11/07/2019 09:08:06 AM
#120 Gap filled. Next leg up? Gtrading 07/08/2019 08:22:27 PM
#119 APTO NEWS Aptose Presents New Preclinical Data for ALERTS100%to10000%GAIN 06/14/2019 07:04:03 AM
#118 Does anyone have a clue why APTO had mte1955 04/03/2019 11:24:45 AM
#117 So I guess April 1 was no big deal? mte1955 04/02/2019 10:38:17 AM
#116 $APTO SELL Book Value Per Share (mrq) $0.40 BottomBounce 03/18/2019 02:31:50 PM
#115 On my radar for April 1, presentations. crudeoil24 03/01/2019 08:03:53 AM
#114 APTO NEWS https://finance.yahoo.com/news/aptose-present-cg-806-apto-120000921.html G2G 03/01/2019 07:27:48 AM
#113 Gap filled Gtrading 10/09/2018 04:06:17 PM
Post Subject